HDAC3 Inhibitor–Checkpoint Blockade Combination for MHC II Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments, particularly for immune-suppressive cancers, are ineffective, necessitating the development of combination therapies that harness the immune system to target cancer cells.
Innovation Solution
Combining a selective histone deacetylase 3 (HDAC3) inhibitor with an immunotherapy agent, such as monoclonal antibodies to PD-1, PD-L1, or CTLA-4, to increase MHC class II expression, enhancing the immune response against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then treatment simplicity is maintained, but treatment effectiveness is insufficient for immune-suppressive cancers
Solution Approach 1:
The patent combines a selective HDAC3 inhibitor with an immune checkpoint inhibitor in a single treatment regimen. The HDAC3 inhibitor increases MHC class II expression on antigen-presenting cells, while the immune checkpoint inhibitor enhances T-cell activation. This combination therapy resolves the contradiction by merging two mechanisms that work synergistically to overcome immune suppression in cancer, achieving superior effectiveness compared to monotherapies while maintaining a manageable treatment complexity through coordinated administration of both agents.
2Reliability
If selective HDAC3 inhibitor is used alone, then MHC class II expression is increased, but overall immune response against cancer is insufficient
Solution Approach 1:
The HDAC3 inhibitor acts as an intermediary that prepares the immune system for enhanced response by upregulating MHC class II expression on antigen-presenting cells. This intermediary effect creates a more favorable immune microenvironment that amplifies the subsequent action of the immune checkpoint inhibitor. The combination resolves the contradiction by using the HDAC3 inhibitor as a facilitator that enables the immune checkpoint inhibitor to achieve stronger anti-tumor immunity, with both agents contributing to a coordinated immunotherapeutic effect.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
Compositions and kits comprising a selective HDAC3 inhibitor in combination with an immunotherapy agent (e.g. an immune checkpoint inhibitor) for use in the treatment of cancer.